Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 5/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 8/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905254 | 0.87 | DNPH1 (0.42) | HPRT1DNPH1P2RX7FGFR1SLC22A6 | |
| SCHEMBL6902586 | 0.86 | HPRT1 (0.43) | HPRT1DNPH1FGFR1SLC22A6CYP3A4 | |
| SCHEMBL6899488 | 0.84 | HPRT1 (0.47) | HPRT1FGFR1SLC22A6FBP1CYP3A4 | |
| SCHEMBL6898237 | 0.83 | FGFR1 (0.56) | HPRT1FGFR1SLC22A6CYP3A4 | |
| SCHEMBL6905969 | 0.83 | FDPS (0.51) | HPRT1P2RX7FGFR1SLC22A6FGFR4 | |
| SCHEMBL6904563 | 0.83 | HPRT1 (0.48) | HPRT1FGFR1SLC22A6FBP1CYP3A4 | |
| SCHEMBL6687661 | 0.83 | HPRT1 (0.48) | HPRT1FGFR1SLC22A6FBP1CYP3A4 | |
| SCHEMBL6897528 | 0.83 | HPRT1 (0.48) | HPRT1FGFR1SLC22A6FBP1CYP3A4 | |
| SCHEMBL6903285 | 0.82 | HPRT1 (0.45) | HPRT1FGFR1SLC22A6FBP1CYP3A4 | |
| SCHEMBL6693987 | 0.80 | HPRT1 (0.46) | HPRT1FGFR1SLC22A6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | HPRT1 871/4885DNPH1 397/4885P2RX7 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.